Description
SEMA6A, the first identified class 6 semaphorin, is contributed to regulate vascular development and adult angiogenesis. SEMA6A could inhibit proliferation, migration, and invasion in different glioma cell lines. That SEMA6A may be a potential prognostic biomarker in the treatment of GBM. Among different semaphorins tested by reverse transcriptase-polymerase chain reaction in human immune cells, the expression of class 6 transmembrane semaphorin SEMA6A was restricted to dendritic cells (DCs)